Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -92.44% is 489% below its 4-year average of 23.75%, near the low end of its 4-year range (-92.44%–76.03%).
As of the fiscal period ended Wednesday, December 31, 2025. 221.81% below its 12-month average of -28.72%.
Annual fiscal-year return on equity; no daily interpolation. Historical series through 2025-12-31.
RETURN ON EQUITY (ROE)
-92.44%
RETURN ON EQUITY (ROE) AVG TTM
-28.72%
RETURN ON EQUITY (ROE) AVG 3Y
10.69%
RETURN ON EQUITY (ROE) AVG 5Y
N/A
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-221.81%
CURRENT VS 3Y AVG
-965.14%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.89%
median of 684 covered companies
CURRENT VS SECTOR MEDIAN
-126.07%
vs the sector median at left
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares
Market Cap
$5.70M
Return on Equity (ROE)
-92.44%
TTM Avg
-28.72%
3Y Avg
10.69%
5Y Avg
N/A
Market Cap
$5.61M
Return on Equity (ROE)
-92.08%
TTM Avg
-1221.97%
3Y Avg
-730.41%
5Y Avg
-532.44%
Market Cap
$5.77M
Return on Equity (ROE)
-76.07%
TTM Avg
-61.76%
3Y Avg
-59.53%
5Y Avg
-66.20%
Market Cap
$5.79M
Return on Equity (ROE)
-34.33%
TTM Avg
-90.47%
3Y Avg
-81.08%
5Y Avg
-76.07%
Market Cap
$5.82M
Return on Equity (ROE)
-111.42%
TTM Avg
-84.56%
3Y Avg
-107.54%
5Y Avg
-308.31%
Market Cap
$5.98M
Return on Equity (ROE)
-87.12%
TTM Avg
-90.45%
3Y Avg
-143.11%
5Y Avg
-272.17%
Market Cap
$5.41M
Return on Equity (ROE)
-156.94%
TTM Avg
-121.17%
3Y Avg
-95.34%
5Y Avg
-84.55%
Market Cap
$5.92M
Return on Equity (ROE)
-59.21%
TTM Avg
-23.87%
3Y Avg
-948.19%
5Y Avg
-660.49%
Market Cap
$5.37M
Return on Equity (ROE)
-225.57%
TTM Avg
-289.16%
3Y Avg
-245.03%
5Y Avg
-192.04%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (CUPR) | $5.70M | -92.44% | -28.72% | 10.69% | N/A |
| Acurx Pharmaceuticals, Inc. (ACXP)vs › | $5.61M | -92.08% | -1221.97% | -730.41% | -532.44% |
| enVVeno Medical Corporation (NVNO)vs › | $5.77M | -76.07% | -61.76% | -59.53% | -66.20% |
| Sonoma Pharmaceuticals, Inc. (SNOA)vs › | $5.79M | -34.33% | -90.47% | -81.08% | -76.07% |
| Lucyd, Inc (LUCY)vs › | $5.82M | -111.42% | -84.56% | -107.54% | -308.31% |
| Cardio Diagnostics Holdings, Inc. (CDIO)vs › | $5.98M | -87.12% | -90.45% | -143.11% | -272.17% |
| Pulmatrix, Inc. (PULM)vs › | $5.41M | -156.94% | -121.17% | -95.34% | -84.55% |
| Scienture Holdings, Inc. (SCNX)vs › | $5.92M | -59.21% | -23.87% | -948.19% | -660.49% |
| Intelligent Bio Solutions Inc. (INBS)vs › | $5.37M | -225.57% | -289.16% | -245.03% | -192.04% |
| Soligenix, Inc. (SNGX)vs › | $5.37M | -154.08% | -205.06% | -23.78% | -114.15% |
ROE
-92.4%
ROA
-55.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2025-12-31 | -92.44% |
| 2024-12-31 | 34.99% |
| 2023-12-31 | 38.64% |
| 2022-12-31 | 61.55% |
| 2021-12-31 | 76.03% |
